Omeros | OMER - Equity Capital And Reserves


Omeros reported $-228.68M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Adma Biologics USD 477.32M 46.13M Dec/2025
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Gilead Sciences USD 22.62B 1.16B Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Immunic USD -6.67M 17.17M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Knight Therapeutics CAD 767.27M 480K Dec/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Rockwell Medical USD 30.41M 1.11M Jun/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
United Therapeutics USD 7.1B 506M Dec/2025
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Xoma USD 87.94M 15.5M Sep/2025